Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance

Abstract

The widespread use of antivirals in immunocompromised individuals has led to frequent occurrences of drug-resistant HSV-1 infections. Current antivirals target the viral DNA polymerase, resulting in cross-resistance patterns that emphasize the need for novel treatment strategies. In this study, we assessed whether combining antivirals with different targets affects drug-resistance emergence by passaging wild-type HSV-1 under increasing concentrations of acyclovir (ACV), foscarnet (PFA), or the helicase-primase inhibitor pritelivir (PTV), individually or in combination (ACV+PTV or PFA+PTV). The resistance selection procedure was initiated from two different drug concentrations for each condition. Deep sequencing and subsequent phenotyping showed the rapid acquisition of resistance mutations under monotherapy pressure, whereas combination therapy resulted in either no mutations or mutations conferring ACV and/or PFA resistance. Notably, mutations associated with PTV resistance were not detected after five passages under combination pressure. Strains resistant to both ACV and PTV were eventually obtained upon further passaging under ACV+PTV pressure initiated from lower drug concentrations. PFA+PTV dual-treatment induced PFA resistance mutations in the DNA polymerase, but PTV-resistance mutations were not acquired, even after 15 passages. Our data suggest that combining the helicase-primase inhibitor PTV with a DNA polymerase inhibitor may be an effective strategy to prevent drug-resistance evolution in HSV-1.